Elan
Executive Summary
By the year 2003, Elan is hoping to be a top 50 pharmaceutical company with $2 bil. in revenues and $20 bil. in market capital, Elan Pharmaceuticals CEO Paul Goddard, PhD, declared Jan. 13 at the H&Q conference in San Francisco. Goddard reported estimated revenues of approximately $650 mil. for 1998, with $250 mil. in estimated U.S. sales for the year. The company expects approval of its anti-convulsant therapy Zonegram in the second quarter of 1999, Goddard said. Zonegram (zonisamide) received an "approvable" letter from FDA in March 1998, but the company did not respond until recently when the Zonegram database was updated to include the Japanese experience. The company also filed a BLA for its cervical dystonia therapy Neurobloc (botulinum toxin type B) in December, and has two NDA filings for Ziconotide for chronic pain and Miguard migraine therapy planned for the first quarter of 1999